Oncogene fusion protein peptide vaccines
US6156316A · kind A · utility
11Cited by
2References
8Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | May 8, 1995 |
| Grant date | Dec 5, 2000 |
| Priority date | — |
| Expiry date | May 8, 2015 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/81
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Fusion-point spanning peptides, for example BCR-ABL fusion breakpoint peptides associated with chronic myelogenous leukemia (CML), bind major histompatibility complex molecules, such as HLA class I molecules, and induce cytotoxic T cell proliferation. The breakpoint peptides can be used as vaccines.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.